CloudCath Monitoring for Peritoneal Dialysis Infections
(ACT Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: CloudCath

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing the CloudCath device, which connects to home dialysis machines to check for infections. It targets patients on peritoneal dialysis who are at risk of peritonitis. The device monitors the dialysis fluid and alerts both the patient and their doctor if it detects possible signs of infection.

Eligibility Criteria

This trial is for individuals currently using in-home peritoneal dialysis, who can give informed consent and will follow the study's requirements. They must have cellular data at home. People with recent cancer treatments, peritonitis, current infections, or involvement in other studies that could affect results are excluded.

Inclusion Criteria

Provides informed consent

I am currently on peritoneal dialysis.

Willing to comply with the requirements of the study

+1 more

Exclusion Criteria

I have not had signs of an infection in the last 14 days.

Participating in another investigational device or drug study that may potentially affect study results

I have had cancer treatment within the last 6 months.

+2 more

Participant Groups

The CloudCath System is being tested to see if it can detect infections from peritoneal dialysis quicker or as quickly as existing methods. The goal is to improve early infection detection which is crucial for patients undergoing this treatment.

1Treatment groups

Experimental Treatment

Group I: CloudCath detectionExperimental Treatment1 Intervention

Active monitoring of dialysate effluent by the CloudCath System.